Rokit Healthcare is showing strength on the 29th, surging more than 7% during the trading session. It is trading at 47,700 won, up 3,200 won (7.19%) from the previous trading day, as positive securities industry assessments of second-half business momentum have boosted investor sentiment.

SK Securities recently published a new report titled "Focus on Second-Half Momentum" and assigned an investment opinion of "Not Rated." In this report, SK Securities cited three key reasons.

First, it identified the positively announced four-year follow-up results of the Egypt treatment case as a major anticipated catalyst. Second, the second half is expected to bring various growth drivers, including the possibility of signing a main contract with Northwell Health in the United States and entering new clinical trials. Third, it projected that revenue will begin to expand in earnest from 2027 rather than this year, diagnosing that a mid- to long-term perspective is needed to evaluate corporate value rather than focusing on short-term performance.

However, it added that due to the nature of biotech companies, performance and stock price volatility could increase depending on clinical trial schedules and contract progress, so related disclosures and business developments should be continuously monitored.

[※ This article is not intended to solicit investment. All final investment decisions and responsibilities lie with the investor.]